Tel Aviv University has developed a new treatment that could treat pancreatic cancers in just two weeks.
Pancreatic cancer is one of the most difficult cancers to treat, with most people with the cancer not living even five years after their diagnosis.
A study found that daily injections for 14 days of a molecule called PJ34 caused the self-destruction of cancerous cells by up to 90 percent. The study was completed with xenografts, transplantation of human pancreatic cancer into immunocompromised mice.
The research was led by Prof. Malka Cohen-Armon and her team at TAU's Sackler Faculty of Medicine in conjunction with Dr. Talia Golan's team at the Cancer Research Center at Sheba Medical Center.
PJ34 causes an anomaly during mitosis of human cancer cells, initiating rapid cell death, meaning that as the cells die as they try to reproduce. The injection appears to have no adverse side effects, according to Cohen-Armon.
Although currently in mice trials, Cohen-Armon said she expects to start testing on humans within two years, assuming the study is granted access to funding.